Hosted on MSN1mon
FDA Expands Approval of Esketamine for Depression
The FDA approved esketamine (Spravato) nasal spray as monotherapy ... differences of -5.1 with the 56-mg dose and -6.8 with the 84-mg dose. In a post-hoc analysis, esketamine yielded numerical ...
pharmaphorum3d
J&J’s Spravato for depression ‘should be much cheaper’
Johnson & Johnson has priced its new Spravato nasal spray for treatment ... March – has a wholesale acquisition cost of $295 per 28 mg device and costs around $32,400 for a year’s treatment ...
Yahoo1mon
FDA approves Spravato as first stand-along nasal spray to treat drug-resistant depression
41,366 people played the daily Crossword recently. Can you solve it faster than others?41,366 people played the daily Crossword recently. Can you solve it faster than others?
Wane1mon
Viking Psychiatry: Spravato Approved as a Monotherapy
Living Local 15 host Jessica Williams is joined by Sean Goddard, a Psychiatric Nurse Practitioner and Owner of Viking Psychiatry, to speak about the recent approval for Spravato as a monotherapy ...
MarketWatch1mon
Johnson & Johnson Gets FDA OK For Spravato as Monotherapy
Johnson & Johnson has won Food and Drug Administration expanded approval of its Spravato nasal spray as a lone therapy for adults with treatment-resistant depression. J&J on Tuesday said the green ...
pharmaphorum2y
FDA approves Janssen’s ketamine-based nasal antidepressant
The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...
Psychology Today1y
Spravato | Tms Therapy | Sgb | Ketamine Infusions
Stella Mental Health in Westmont specializes in medication management, Spravato (esketamine) nasal spray, transcranial magnetic stimulation (TMS), ketamine infusion therapy, stellate ganglion ...